U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07265414) titled 'DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy' on Nov. 24.
Brief Summary: At the present moment, there is no international consensus on the optimal screening to perform in men with a specific genetic/molecular risk for PCa. The number of studies exploring screening strategies tailored to men with a family history for PCa is limited [15-17]: most of them support the use of targeted screening but methodological differences make it impossible to draw conclusions from these data [18-25]. On the basis of these considerations, we believe extremely important to investigate a new approach t...